Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review
Target: Folate Receptor alpha (FRα)
Product Category: Antibody; Cell; Radiopharmaceutical; Small Molecule; Vaccine
This product provides basic information on approved drugs and drug candidates in research and development targeting folate receptor alpha (FRα).
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for FRα-targeted drugs and drug candidates (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
Folate receptor alpha (FRα) is a cell surface GPI-anchored protein overexpressed in several solid tumors with highest prevalence in ovarian cancer and lung adenocarcinoma but restricted expression in normal tissues. An antibody drug conjugate (ADC) with a microtubule inhibitor (MTI) payload recently received accelerated approval from the FDA for FRα-expressing platinum-resistant ovarian cancer. Thus, folate receptor alpha is clinically validated target with commercial potential.
Folate receptor alpha holds great promise as a target for next generation improved drug candidates based on drug modalities known to enhance effector function and/or to broaden the therapeutic window. Among FRα-targeted drug modalities in use for next generation therapy candidates are ADCs with novel targeting moieties and linker/payload technologies as well as novel small molecule drug conjugates. Furthermore, next generation cell therapy modalities and radiopharmaceuticals are advancing in the pipeline. And T-cell or NK cell engaging bispecific antibodies are further drug modalities applied to folate receptor alpha therapies.